Next Article in Journal
Anti-Inflammatory Drugs as Anticancer Agents
Next Article in Special Issue
Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition
Previous Article in Journal
Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction
Previous Article in Special Issue
MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Role of microRNAs in Venous Thromboembolism

by
Vânia M. Morelli
1,*,
Sigrid K. Brækkan
1,2 and
John-Bjarne Hansen
1,2
1
K.G. Jebsen Thrombosis Research and Expertise Center (TREC), Department of Clinical Medicine, UiT—The Arctic University of Norway, N-9037 Tromsø, Norway
2
Division of Internal Medicine, University Hospital of North Norway, N-9037 Tromsø, Norway
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(7), 2602; https://doi.org/10.3390/ijms21072602
Submission received: 13 March 2020 / Revised: 5 April 2020 / Accepted: 6 April 2020 / Published: 9 April 2020
(This article belongs to the Special Issue MicroRNAs as Biomarkers and Effector Molecules of Thrombosis)

Abstract

MicroRNAs (miRNAs) are non-coding RNAs that execute their function by targeted downregulation of gene expressions. There is growing evidence from epidemiological studies and animal models suggesting that the expression level of miRNAs is dysregulated in venous thromboembolism (VTE). In this review, we summarize the current knowledge on the role of miRNAs as biomarkers for VTE and provide general insight into research exploring the modulation of miRNA activity in animal models of venous thrombosis. Up to now, published studies have yielded inconsistent results on the role of miRNAs as biomarkers for VTE with most of the reports focused on diagnostic research. The limited statistical power of the individual studies, due to the small sample sizes, may substantially contribute to the poor reproducibility among studies. In animal models, over-expression or inhibition of some miRNAs appear to influence venous thrombus formation and resolution. However, there is an important gap in knowledge on the potential role of miRNAs as therapeutic targets in VTE. Future research involving large cohorts should be designed to clarify the clinical usefulness of miRNAs as biomarkers for VTE, and animal model studies should be pursued to unravel the role of miRNAs in the pathogenesis of VTE and their potential as therapeutic targets.
Keywords: microRNAs; venous thromboembolism; venous thrombosis; biomarker; animal model microRNAs; venous thromboembolism; venous thrombosis; biomarker; animal model

Share and Cite

MDPI and ACS Style

Morelli, V.M.; Brækkan, S.K.; Hansen, J.-B. Role of microRNAs in Venous Thromboembolism. Int. J. Mol. Sci. 2020, 21, 2602. https://doi.org/10.3390/ijms21072602

AMA Style

Morelli VM, Brækkan SK, Hansen J-B. Role of microRNAs in Venous Thromboembolism. International Journal of Molecular Sciences. 2020; 21(7):2602. https://doi.org/10.3390/ijms21072602

Chicago/Turabian Style

Morelli, Vânia M., Sigrid K. Brækkan, and John-Bjarne Hansen. 2020. "Role of microRNAs in Venous Thromboembolism" International Journal of Molecular Sciences 21, no. 7: 2602. https://doi.org/10.3390/ijms21072602

APA Style

Morelli, V. M., Brækkan, S. K., & Hansen, J.-B. (2020). Role of microRNAs in Venous Thromboembolism. International Journal of Molecular Sciences, 21(7), 2602. https://doi.org/10.3390/ijms21072602

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop